Introduction The diagnosed type 2 diabetes population continues to rise on the back of aging and obesity rates, expanding the market potential for modern insulins. Biosimilar modern insulins are forecast to impact seven major market sales from 2014, raising new barriers for market entry. Features and benefits Forecast leading insulin antidiabetic brands in the 2011–20 period Quantify the sales potential of late-stage pipeline products Degludec and Degludec Plus Assess the impact of biosimilar competition on insulin analog brands Determine the impact of recent clinical trial results and regulatory decisions
Highlights The modern insulins market as a whole is forecast to grow over the 2011–20 forecast period, with basal insulins having the largest market share. Biosimilars are expected to enter all markets from 2014, and are forecast to contribute 19% of 2020 value sales. The US has the largest contribution to key modern insulins sales, and is forecast to reach sales of $12bn in 2020. Germany has high insulin as physicians are willing to switch type 2 patient to insulin relatively early in the course of the disease, while in Japan lower insulin dosages per patient mean that the value contribution is low. Late-stage pipeline insulins forecast to launch over 2011–20 are the Novo Nordisk basal insulin products Degludec and Degludec Plus. Insulin degludec is forecast to provide a stronger competitor to Lantus than Novo Nordisk’s currently marketed Levemir. Your key questions answered Use the Datamonitor patient-based forecast to quantify key insulin product sales at country, class, molecule and brand levels Identify which brands will grow in the 2011–2020 forecast period and which markets are more receptive to growth Use volume data to understand market trends and biosimilar impact
Contains 62 pages and
|